Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (600)	6/28/1999 3:51:00 PM
From: Mike McFarland	Respond to of 1494

I stand corrected, good news will consist of a partnership, financing, or data from any of the several trials. Good or bad news cannot probably be inferred from fluctuations in the stock price--whether those moves are driven by Neuroinvestment's letter or apparent dilution due the private offering. The volume is just too light, it's probably the same 50k shares turning over, and mainly just by a few folks, perhaps including those of us on this thread. Regarding the offering of additional shares... I'd vote for NTI to instead take any offer of a loan from Merz. By the way, if you get a chance to listen to the vcall Biospace recording, it was fun to hear the comments about retail investors and "chat rooms". There is a break right now...then "Next Generation Technologies: Changing the face of drug development" Lewis Shuster President and Chief Operating Officer Pharmacopeia will be on that panel.